1. The recent development of a series of novel KATP channel modulators, namely sulphonylthioureas and sulphonylureas, is thought to make improvements in potency and tissue selectivity compared with current sulphonylureas, such as glibenclamide, which shares a similar structure to the novel compounds.
INTRODUCTION
The aetiology of overt non-insulin-dependent diabetes mellitus (NIDDM) is complex, but is clearly characterized by chronic hyperglycaemia. It is associated with multiple defects, namely impaired insulin secretion from pancreatic ␤-cells as well as insulin resistance in peripheral tissues. Non-insulin-dependent diabetes mellitus is a progressive disease, such that the spiralling cycle of hyperinsulinaemia and insulin resistance ultimately leads to the hypoinsulinaemia and ultimately macrovascular and microvascular complications if not adequately controlled.
There have been several main approaches to the pharmacological control of NIDDM. First, sulphonylureas, such as glibenclamide, improve insulin secretion by blocking pancreatic KATP channels. Metformin and the thiazolidinediones, in contrast, both elicit their action by improving insulin sensitivity. Metformin specifically decreases hepatic glucose production and promotes insulinmediated glucose uptake in muscle. 1 The main mechanism of action of thiazolidinediones is in adipose tissue, where they have been shown to have high affinity for the peroxisome proliferator-activated ␥ receptor (PPAR␥). This results in adipocyte differentiation and favours insulin sensitivity. [2] [3] [4] The present pharmacological approaches to NIDDM are far from ideal. The most common and disturbing side effect of many sulphonylureas is hypoglycaemia, because a deficiency in glucose concentration of less than 2 mmol/L increases the risk of neurological damage. 5 Despite the popular use of metformin, it has been associated with serious side effects, such as lactic acidosis as well as weight loss and the milder gastrointestinal disturbances. [6] [7] [8] Although lactic acidosis is rare among patients taking metformin, mortality risks for metformin-associated lactic acidosis (MALA) are comparable with glibenclamide-induced hypoglycaemia. 7 In addition, as a result of the action of thiazolidinediones at the adipose tissue, they ultimately promote fat accumulation in the adipose tissue and are not recommended in obese patients. Furthermore, an increased risk of liver failure has been seen in some patients administered the thiazolidinedione troglitazone 9 and this has resulted in its recent removal from the world market. Ultimately, there often is inadequate metabolic control over time with monotherapy because the present pharmacological agents either aim to treat impaired insulin secretion from the pancreas (sulphonylureas) or improve insulin sensitivity in peripheral tissues (metformin and thiazolidinediones), but not both. Combination therapy often occurs because there is no evidence of significant drug interactions with such treatment; 10 however, there are greater demands in terms of complexity of dosing and potential for errors that may result in patient noncompliance.
There is great interest in the development of superior antidiabetic compounds that may have a dual mechanism of action without the side effects experienced with pre-existing treatments. A series of novel sulphonylthioureas and sulphonylureas have been developed as potential alternatives to current diabetic treatment, such as the sulphonylurea glibenclamide. 11 Furthermore, these studies give an insight into the structure-activity relationships and essential structural requirements for activity in the fa/fa Zucker rat, a model of insulin resistance. In order to evaluate the effect of these novel compounds on syndromes seen in NIDDM, we evaluated their effect on glucose tolerance during an oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT) following 5 and 28 days administration in the fa/fa Zucker rat.
METHODS

Drugs
The novel compounds ( Fig. 1) were developed in-house by one of the authors (NC). 11 Metformin and glibenclamide were purchased from Sigma Chemical Co. (St Louis, MO, USA). All compounds were dissolved in 2% carboxymethylcellulose (CMC).
Animals
The obese Zucker rat has an autosomal recessive inheritance and, compared with its lean littermate, it shows insulin resistance with mild but chronic hyperglycaemia, hyperinsulinaemia, hyperlipideamia and glucose intolerance. Male obese fa/fa and lean fa/-Zucker rats were purchased from Monash Animal Services (Monash University, Clayton, Victoria, Australia) at 10-12 weeks of age. They were housed in The Royal Prince Alfred Hospital Animal House (Sydney, NSW, Australia) and allowed to acclimatize for 7 days in an environmentally controlled room at 22°C with an alternating 12 h light/dark cycle (0700-1900 h light). These animals were maintained on normal laboratory chow and water ad libitum. All experiments were performed according to The University of Sydney Animal Care and Ethics Committee guidelines.
Oral glucose tolerance test
day study
The novel compounds in Fig. 1 were evaluated for their effect on glucose tolerance following oral administration at a dose of 0.1 mg/kg per day. Rats were given either a test compound (0.1 mg/kg), glibenclamide (2 mg/kg per day), metformin (300 mg/kg per day) or vehicle (2% CMC) daily for 5 days by oral gavage. Two OGTT were performed in each rat, the first as a baseline (before drug) and the second after 5 days of drug treatment. Rats were fasted overnight (16 h) then administered the test compound, followed 2 h later with a 3 g/kg bodyweight 50% glucose (w/v; Baxter Healthcare, Old Toongabbie, NSW, Australia). Tail blood sampling was taken 0, 0.5, 1, 1.5, 2 and 3 h after the oral glucose load. Serum glucose concentrations were then measured in duplicate using the glucose oxidase method (Glucose Trinder Reagent Kit; Sigma Chemical Co.). Samples were assayed using a Hitachi (Tokyo, Japan) U-200 spectrophotometer at a wavelength of 505 nm. In addition, the weight gain of each rat was recorded over the 5 day treatment period and all results were compared with both the negative control group (vehicle only) and the positive control groups (glibenclamide or metformin).
Obese fa/fa rats underwent an initial OGTT and were then given treatment (either compound 3-15, metformin or control) for 28 days.
Intravenous glucose tolerance test
day study
Obese rats were fasted overnight (16 h) and then given their final treatment (day 28) by oral gavage, 2 h before the commencement of their IVGTT. Rats were then anaesthetized with an intraperitoneal injection of sodium pentobarbitone (30 mg/kg) and ketamine (10 mg/kg) and kept under sedation for the duration of the experiments with ketamine (5 mg/kg). Anaesthetized rats were monitored for signs of consciousness by leg pinch reflex. Animals were kept warm on a heat mat throughout the anaesthetized state to prevent hypothermia. Rats were shaved at the front nape of the neck. The trachea was isolated and a plastic tube was inserted to assist with breathing during the experiment. The right jugular was isolated, tied off and then an incision was made to insert the cannula that was then flushed with heparinized saline (1000 U/mL) to maintain patency. 
It is known that sodium pentobarbitone can cause metabolic changes that can affect glucose turnover. 12 However, blood glucose levels appear to return to those observed in the awake state 30-40 min after an injection of sodium pentobarbitone. 13 Studies have also revealed that the stress response to surgery in acutely operated anaesthetized rats subsides within 1 h. 14 In light of this, 45 min following the induction of anaesthesia, a fasting blood sample was taken. The IVGTT was commenced with a glucose load of 1 g/kg 50% glucose (w/v) and blood samples for glucose and insulin analyses were then collected in heparinized tubes at 2, 4, 6, 8, 10, 15, 30, 45 and 60 min following the glucose load. Plasma glucose was measured by the glucose oxidase method. Plasma insulin concentration was measured by radioimmunoassay using Linco antibodies (Linco, St Louis, MO, USA) and rat insulin standards (0-8 ng/mL; Novo Biolabs, Bagsvaerd, Denmark).
Data analysis
The mean plasma glucose concentration and insulin concentration were determined for each sampling time of the OGTT and IVGTT and the mean plasma levels were plotted against time. The mean area under the curve (AUC) was calculated for the drug-treated group and was compared with the control group using a single-factor analysis of variance (ANOVA). A single-factor ANOVA was also performed on the baseline, peak (maximum) and 3 h glucose levels (OGTT) or 1 h glucose levels (IVGTT) in the drug-treated group and compared with control. This was repeated for measurement of insulin concentrations. Fisher's protected least significant difference (PLSD) test was used for post hoc analysis. Results were considered statistically significant when P < 0.05.
RESULTS
day study
Results of an investigation into the effects induced by the novel compounds on fasting plasma glucose concentrations are shown in Fig. 2 . All Zucker rats showed a similar glucose tolerance profile before commencement of treatment (data not shown) and, as a consequence, all results presented here are following 5 days of treatment. The sulphonylthiourea 1-24 (n = 5) and sulphonylurea 3-4 (n = 6) significantly worsened fasting plasma glucose concentration in the Zucker fa/fa rat (P < 0.05). Compounds with the sulphonylthiourea moiety in the 4-position, either significantly lowered (P < 0.05) fasting plasma glucose concentration (compound 3-14 (n = 5); compound 3-16 (n = 6)) to that of the control fa/-rat (n = 8), whereas the remainder had no significant effect. Metformin (n = 10) did not induce a significant improvement in basal hyperglycaemia compared with the control Zucker fa/fa rat (n = 18).
Maximum plasma glucose levels ( Fig. 3) were observed 1 h following the oral glucose load, except in animals dosed with metformin or compound 3-15, where the maximal values occurred at approximately 30 min after the glucose load was administered. Glibenclamide (n = 6) and compound 1-24 showed a significant increase in the maximum plasma glucose concentration compared with the control fa/fa Zucker rat (P < 0.05). The sulphonylurea 3-4 and the sulphonylthioureas 3-16 and 3-12 (n = 5) had no significant effect on the maximal plasma glucose concentrations. Metformin significantly reduced the maximal plasma glucose concentration to that observed in the fa/-Zucker rat (P < 0.05), while the sulphonylthioureas 3-15 and 3-14 significantly reduced maximal plasma glucose levels to a lesser extent.
Rats administered glibenclamide for 5 days maintained plasma glucose concentrations significantly greater than the control obese Zucker rats, even 3 h after the administration of the glucose load ( Fig. 4 ; P < 0.05). Metformin had no significant effect, while compounds 3-15 and 3-16 with the sulphonylthiourea moiety in the 4-position lowered the 3 h plasma glucose concentration to the level of that observed in the fa/-Zucker rat.
Improvement in total glucose tolerance over a 3 h period (Fig. 5 ) was measured as the AUC. For compounds that appeared to worsen glucose tolerance over the 3 h period, the results correlated with those observed in Fig. 4 . With the exception of compound 3-12, all compounds with the sulphonylthiourea moiety in the 4-position significantly improved glucose tolerance. Metformin (300 mg/kg per day) and compound 3-15 (0.1 mg/kg per day) improved glucose tolerance to the extent that it was not significantly different from the fa/-Zucker rat. Despite there being a trend to towards an increase in weight gain in glibenclamide-treated fa/fa rats, this was not statistically significant. Furthermore, there was no significant change in weight gain in any of the other treated rats (data not shown). None of the fa/-Zucker rats treated with glibenclamide, metformin or novel agents showed a significant change in glucose tolerance compared with control fa/-Zucker rats (data not shown).
Long-term studies with compound 3-15 (n = 6) showed a significant improvement (P < 0.05) in glucose clearance (Fig. 6 ) in fa/fa Zucker rats compared with control (n = 4) and this paralleled that seen in metformin-treated rats (n = 5; P < 0.05). Figure 7 shows the basal (0), maximal (10 min) and final (60 min) insulin concentration in these rats. There was a significant rise in plasma insulin concentration following the glucose load in all treated rats. Both metformin-and compound 3-15-treated rats showed a decrease in insulin concentration compared with untreated control rats at 0, 10 and 60 min, with the results with compound 3-15 being significantly lower (P < 0.05) at all these time points, while metformin showed significance at 60 min only. Although compound 3-15 appeared to lower insulin levels compared with metformin at all time points, this was not significant. The rate of weight gain in compound 3-15-treated rats was not significantly different from that seen in control rats, whereas metformin showed a trend towards an increase in the rate of weight gain (data not shown).
DISCUSSION
Structure-activity correlations
The sulphonylthiourea 3-15, when administered to the obese, insulin-resistant Zucker fa/fa rats, showed the greatest improvement in glucose tolerance compared with other compounds from this series. This may indicate the presence of a different and possibly second form of activity to that generally observed with sulphonylureas. Indeed, this activity was not present when sulphonylureas, glibenclamide or novel compound 3-4 were administered. When the ethoxy group of compound 3-15 was replaced with a bromine atom (compound 3-12), activity was lost. Similarly, substitution of the ethoxy group of compound 3-15 with a methoxy (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) or propoxy (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) group reduced the overall improvement in glucose tolerance but did significantly reduce fasting plasma glucose concentrations compared with control. Furthermore, these results suggest that the improvement in glucose clearance seen with compound 3-15 may be due to the sulphonythiourea group being substituted into the 3-or 4-position of the pyridine group compared with the 2-position (compound 1-24). This activity is increased when the pyridyl moiety is further substituted in the 2-and/or 6-position with electron-withdrawing groups other than bromine. The urea compound 3-4 lacked activity compared with sulphonylthiuorea compounds, thus revealing that the thiourea group was important for activity in the Zucker fa/fa rats. These structure-activity relationships are summarized in Fig. 8 .
Pharmacology
day study
Metformin improved glucose tolerance in Zucker fa/fa rats and these results are in agreement with the established hypothesis that metformin improves peripheral insulin sensitivity without affecting insulin secretion. 15 The sulphonylureas, glibenclamide and compound 3-4 appear to have little benefit in the fa/fa Zucker rat due to their inability to improve glucose clearance in this insulinresistant model. The worsening of glucose tolerance seen in glibenclamide-treated fa/fa rats is supported by Hargrove et al. 15 Although these authors suggest that the exacerbation of glucose intolerance could be the result of a decompensation measure, this is only a hypothesis because insulin was not measured in their study. Pre-and post-receptor studies would highlight whether the administration of a KATP channel modulator, such as glibenclamide, which further increases insulin secretion (thus worsening hyperinsulinaemia), may be enough to cause downregulation of the insulin receptors on insulin target tissues. This is despite the fa/fa Zucker rats usually remaining hyperinsulinaemic throughout their life in order to overcome peripheral insulin resistance. Hargrove et al. 15 did show that sulphonylureas had decreased 2-deoxyglucose uptake compared with the thiazolidinedione CP-68 722 in fa/fa Zucker rats. The defect in glucose disposal is thought to worsen despite the plasma insulin response not being affected. In contrast, Tokuyama et al. 17 have shown that diabetic fa/fa Zucker rats have fewer KATP channels despite a significant change in sulphonylurea receptor mRNA levels. In view of these findings, it would be important to determine whether the worsening of glucose tolerance in glibenclamide-treated rats was the result of decompensation of the insulin receptors. The effect of compound 1-24 (0.1 mg/kg per day) on glucose clearance appeared to parallel that seen with glibenclamide (2 mg/kg per day). It can be postulated that this potent novel agent may have a similar mechanism of action to that of glibenclamide in improving insulin secretion from the pancreas due to its action in Sprague-Dawley rats 11 and lack of activity in the fa/fa Zucker rat. The activity of the other novel compounds can be explained in relation to their structure, as discussed earlier. They all elicited a response to the glucose load, as shown by the rise in plasma glucose from fasting values. The ability of compounds 3-15 and 3-14 to decrease the maximum plasma glucose levels means that these compounds may be having an effect on glucose uptake or production. If they were acting on insulin secretion alone, there would be little effect on the plasma glucose values because the fa/fa Zucker rats are already hyperinsulinaemic. Furthermore, because compound 3-15 and metformin had peak plasma glucose concentrations as early as 30 min following the glucose load, this may indicate a faster mechanism of action compared with the other novel compounds. Only compounds 3-15 and 3-16 were able to return plasma glucose levels to pre-OGTT values, 3 h following the glucose load. Therefore, both these compounds have the ability to elicit a normal response to a glucose load in the fa/fa Zucker rat despite the defect in insulin sensitivity in this rat strain.
As expected, no significant change in glucose concentration was seen in lean Zucker fa/-rats following 5 days of metformin treatment (data not shown). Unlike the fa/fa Zucker rats, these fa/-rats do not display a defect in metabolic activity and, therefore, improving their insulin sensitivity further would have no impact on their blood glucose levels. Metformin is often used in obese NIDDM subjects due to its anoretic effect, 18 but no significant reduction in weight gain over 5 days was seen in metformin-treated Zucker fa/fa rats despite there being a trend towards weight gain reduction with this compound (data not shown). Glibenclamide is not recommended in grossly obese NIDDM patients due to its ability to cause excessive weight gain. 8 Glibenclamide-treated Zucker fa/fa rats showed the greatest increase in the rate of weight gain compared with control, although this was not statistically significant (data not shown).
Of most interest were the results of compound 3-15, which showed a significant improvement in glucose tolerance compared with control fa/fa Zucker rats as determined by a significant improvement in AUC. This novel compound showed comparable activity to metformin but at a dose 3000-fold less than in the metformintreated rats.
The improved glucose clearance in compound 3-15-treated rats, together with the decrease in the insulin concentration, may suggest that compound 3-15 is improving insulin sensitivity in the insulin-resistant rat. However, it is yet to be determined how this is achieved exactly. The effect of compound 3-15 on insulin secretion has yet to be established but, being a sulphonylthiourea, it shares some similarities with the insulin sensitizers, namely, sulphonylureas. It would be important to see whether compound 3-15 to improve insulin sensitivity as well as insulin secretion, thus making it a superior compound for the treatment of NIDDM.
In conclusion, the improvement in glucose tolerance with a number of the novel compounds observed in the fa/fa Zucker rat can be correlated with structural modifications made to these novel compounds. Consequently, the ability of compound 3-15 to improve glucose tolerance in the fa/fa Zucker rat following 5 days treatment as well as improve glucose clearance and decrease insulin concentration following 28 days of treatment, illustrate its potential as an antidiabetic agent. Furthermore, these results provide a greater insight into the essential structural characteristics needed for an active antidiabetic compound in the fa/fa Zucker rat.
